It is a TRIDENT-1 trial (NCT03093116) drug and showed an overall response rate of 14.8 (7.6–NE) months and a progression-free survival of 9.0 (6.8–19.7) months among ROS-1-positive NSCLC patients previously treated with ROS1 TKI and platinum-based chemotherapy (Cho et al., 2023). The gene discussed is ROS1; the disease is non-small cell lung carcinoma.